Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19762224 | 0.91 | LPL (0.43) | LPLLIPGKMT2AKDM4EPDGFRB | |
| SCHEMBL19299388 | 0.88 | LIPG (0.47) | LPLLIPGKMT2AKDM4EPDGFRB | |
| SCHEMBL24839900 | 0.84 | LPL (0.56) | LPLLIPGKDM4EKDRALDH1A1 | |
| SCHEMBL21065676 | 0.84 | LIPG (0.59) | LPLLIPGKMT2APDGFRBKDR | |
| SCHEMBL30951709 | 0.84 | LIPG (0.59) | LPLLIPGKMT2APDGFRBKDR | |
| SCHEMBL12999308 | 0.83 | LIPG (0.56) | LPLLIPGPDGFRBKDR | |
| SCHEMBL16788914 | 0.83 | LIPG (0.62) | LPLLIPGPDGFRBKDR | |
| SCHEMBL31106 | 0.82 | LIPG (0.59) | LPLLIPGPDGFRBKDRALDH1A1 | |
| SCHEMBL21207856 | 0.81 | LPL (0.46) | LPLLIPGKMT2AKDM4EPDGFRB | |
| SCHEMBL31625558 | 0.80 | LIPG (0.53) | LPLLIPGPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023277289-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 엘티소재주식회사 | 2023-01-05 | — | — | WO | disclosed |
| US-11538996-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2022-12-27 | — | — | US | disclosed |
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10454041-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2017144150-A2 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10454041-B2 | Materials for organic electroluminescent devices | RIF1, INTS9, LEF1 | LPL 3484/4885LIPG 3521/4885KMT2A 3719/4885 |
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | LPL 3379/4885LIPG 1509/4885KMT2A 115/4885 |
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | LPL 3379/4885LIPG 1509/4885KMT2A 115/4885 |
| US-11538996-B2 | Materials for organic electroluminescent devices | RIF1, INTS9, LEF1 | LPL 3484/4885LIPG 3521/4885KMT2A 3719/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | LPL 3379/4885LIPG 1509/4885KMT2A 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.